Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Meta Expands AI Training With Employee Activity Tracking Tools 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
AUSTIN, Texas, March 29, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will deliver a poster presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting taking place April 1 – 5 in Washington, DC.
Full abstracts are available online at www.aacr.org. Details of the poster presentation are listed below:
Title: Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit
Abstract Number: 3964
Session Title: Tumor Microenvironment 5
Date: Tuesday, April 4
Presentation Time: 8 a.m. – 12 p.m. ET
Location: Walter E. Washington Convention Center, Halls A-C, Poster Section 42
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine. For more information, please visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
